New Psychoactive Substance (NPS) benzodiazepines (AKA designer benzodiazepines) emerged in Europe around 2007, but were first detected and identified in death cases in 2010 in the USA (Bailey et al. 2010) and 2011 in the UK (Maskell et al. 2011a). Since the first NPS benzodiazepines emerged another 20 are being monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), leading to concern that the abuse of NPS benzodiazepines may become a significant global problem. This chapter looks at NPS benzodiazepines, their pharmacology, potency, prevalence, use, abuse, potential poly-pharmacy, risk of hospitalisation, detection in the clinical setting and finally treatment of overdose.
|Title of host publication||Handbook of novel psychoactive substances|
|Subtitle of host publication||what clinicians should know about NPS|
|Editors||Ornella Corazza, Andrew Roman-Urrestarazu|
|Number of pages||22|
|ISBN (Print)||9781138068308, 9781138068292|
|Publication status||Published - 19 Oct 2018|
Maskell, P. D., & Wilson, N. E. (2018). Designer benzodiazepines: new challenges and treatment options . In O. Corazza, & A. Roman-Urrestarazu (Eds.), Handbook of novel psychoactive substances : what clinicians should know about NPS (1st ed., pp. 342-363). Routledge.